Fluoroquinolones' Biological Activities Against Laboratory Microbes and Cancer Cell Lines

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 Mar 10

PMID 35268759

Authors

Ghadeer A R Y Suaifan

Aya A M Mohammed

Bayan A Alkhawaja

Affiliations

Soon will be listed here.

Abstract

Development of novel derivatives to rein in and fight bacteria have never been more demanding, as microbial resistance strains are alarmingly increasing. A multitude of new fluoroquinolones derivatives with an improved spectrum of activity and/or enhanced pharmacokinetics parameters have been widely explored. Reporting novel antimicrobial agents entails comparing their potential activity to their parent drugs; hence, parent fluoroquinolones have been used in research as positive controls. Given that these fluoroquinolones possess variable activities according to their generation, it is necessary to include parent compounds and market available antibiotics of the same class when investigating antimicrobial activity. Herein, we provide a detailed guide on the in vitro biological activity of fluoroquinolones based on experimental results published in the last years. This work permits researchers to compare and analyze potential fluoroquinolones as positive control agents and to evaluate changes occurring in their activities. More importantly, the selection of fluoroquinolones as positive controls by medicinal chemists when investigating novel FQs analogs must be correlated to the laboratory pathogen inquest for reliable results.

Citing Articles

High Carriage of , , and Resistance Genes among the Multidrug-resistant Uropathogenic (UPEC) Strains from Malaysian Patients.

Chin J, Lee H, Lee S, Lee Y, Chew C Trop Life Sci Res. 2024; 35(2):211-225.

PMID: 39234470 PMC: 11371398. DOI: 10.21315/tlsr2024.35.2.10.

Ciprofloxacin Accelerates Angiotensin-II-Induced Vascular Smooth Muscle Cells Senescence Through Modulating AMPK/ROS pathway in Aortic Aneurysm and Dissection.

Zeng W, Liang Y, Huang S, Zhang J, Mai C, He B Cardiovasc Toxicol. 2024; 24(9):889-903.

PMID: 39138741 PMC: 11335803. DOI: 10.1007/s12012-024-09892-z.

Design, synthesis and evaluation of novel norfloxacin analogs as potent anticancer and antioxidant agents.

Qurban F, Shahzad S, Khaskheli M, Khan S, Khan S, Rauf W Future Med Chem. 2024; 16(17):1777-1789.

PMID: 39115052 PMC: 11457674. DOI: 10.1080/17568919.2024.2383165.

Ciprofloxacin and Norfloxacin Hybrid Compounds: Potential Anticancer Agents.

Peter S, Aderibigbe B Curr Top Med Chem. 2024; 24(7):644-665.

PMID: 38357952 DOI: 10.2174/0115680266288319240206052223.

Spectroscopic properties (FT-IR, NMR and UV) and DFT studies of amodiaquine.

Manwal A Mekoung P, Malloum A, Govindarajan M, Mballa R, Patouossa I, Abouem A Zintchem A Heliyon. 2023; 9(12):e22187.

PMID: 38076079 PMC: 10709190. DOI: 10.1016/j.heliyon.2023.e22187.

References

Towle T, Kulkarni C, Oppegard L, Williams B, Picha T, Hiasa H . Design, synthesis, and evaluation of novel N-1 fluoroquinolone derivatives: Probing for binding contact with the active site tyrosine of gyrase. Bioorg Med Chem Lett. 2018; 28(10):1903-1910. PMC: 5938125. DOI: 10.1016/j.bmcl.2018.03.085. View

Li Q, Xing J, Cheng H, Wang H, Wang J, Wang S . Design, synthesis, antibacterial evaluation and docking study of novel 2-hydroxy-3-(nitroimidazolyl)-propyl-derived quinolone. Chem Biol Drug Des. 2014; 85(1):79-90. DOI: 10.1111/cbdd.12395. View

Pfaller M, Sheehan D, Rex J . Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev. 2004; 17(2):268-80. PMC: 387411. DOI: 10.1128/CMR.17.2.268-280.2004. View

Seliem I, Panda S, Girgis A, Nagy Y, George R, Fayad W . Design, synthesis, antimicrobial, and DNA gyrase inhibitory properties of fluoroquinolone-dichloroacetic acid hybrids. Chem Biol Drug Des. 2019; 95(2):248-259. DOI: 10.1111/cbdd.13638. View

Leyva-Ramos S, de Loera D, Cardoso-Ortiz J . In vitro Antibacterial Activity of 7-Substituted-6-Fluoroquinolone and 7-Substituted-6,8-Difluoroquinolone Derivatives. Chemotherapy. 2017; 62(3):194-198. DOI: 10.1159/000456533. View

Ture A, Kulabas N, Dingis S, Birgul K, Bozdeveci A, Karaoglu S . Design, synthesis and molecular modeling studies on novel moxifloxacin derivatives as potential antibacterial and antituberculosis agents. Bioorg Chem. 2019; 88:102965. DOI: 10.1016/j.bioorg.2019.102965. View

Zhang T, Wu J, Chen S, Liu K, Lin Y, Guo H . Synthesis and antibacterial activity of amino acid and dipeptide prodrugs of IMB-070593, a fluoroquinolone candidate. Molecules. 2014; 19(5):6822-37. PMC: 6270849. DOI: 10.3390/molecules19056822. View

Khan Z, Siddiqui M, Park S . Current and Emerging Methods of Antibiotic Susceptibility Testing. Diagnostics (Basel). 2019; 9(2). PMC: 6627445. DOI: 10.3390/diagnostics9020049. View

Xu Z, Zhang S, Feng L, Li X, Huang G, Chai Y . Synthesis and In Vitro Antimycobacterial and Antibacterial Activity of 8-OMe Ciprofloxacin-Hydrozone/Azole Hybrids. Molecules. 2017; 22(7). PMC: 6152256. DOI: 10.3390/molecules22071171. View

10.

Fardeau S, Dassonville-Klimpt A, Audic N, Sasaki A, Pillon M, Baudrin E . Synthesis and antibacterial activity of catecholate-ciprofloxacin conjugates. Bioorg Med Chem. 2014; 22(15):4049-60. DOI: 10.1016/j.bmc.2014.05.067. View

11.

Zhang T, Shen W, Liu M, Zhang R, Wang M, Li L . Synthesis, antimycobacterial and antibacterial activity of fluoroquinolone derivatives containing an 3-alkoxyimino-4-(cyclopropylanimo)methylpyrrolidine moiety. Eur J Med Chem. 2015; 104:73-85. DOI: 10.1016/j.ejmech.2015.09.030. View

12.

Mermer A, Faiz O, Demirbas A, Demirbas N, Alagumuthu M, Arumugam S . Piperazine-azole-fluoroquinolone hybrids: Conventional and microwave irradiated synthesis, biological activity screening and molecular docking studies. Bioorg Chem. 2019; 85:308-318. DOI: 10.1016/j.bioorg.2019.01.009. View

13.

Ibrahim M, Panda S, Birs A, Serrano J, Gonzalez C, Alamry K . Synthesis and antibacterial evaluation of amino acid-antibiotic conjugates. Bioorg Med Chem Lett. 2014; 24(7):1856-61. DOI: 10.1016/j.bmcl.2014.01.065. View

14.

Zhanel G, Walkty A, Vercaigne L, Karlowsky J, Embil J, Gin A . The new fluoroquinolones: A critical review. Can J Infect Dis. 2012; 10(3):207-38. PMC: 3250697. DOI: 10.1155/1999/378394. View

15.

Oliphant C, Green G . Quinolones: a comprehensive review. Am Fam Physician. 2002; 65(3):455-64. View

16.

Idowu T, Schweizer F . Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities. Antibiotics (Basel). 2017; 6(4). PMC: 5745469. DOI: 10.3390/antibiotics6040026. View

17.

Scroggs S, Offerdahl D, Flather D, Morris C, Kendall B, Broeckel R . Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV. Viruses. 2020; 13(1). PMC: 7822115. DOI: 10.3390/v13010008. View

18.

Ji C, Miller P, Miller M . Syntheses and Antibacterial Activity of N-Acylated Ciprofloxacin Derivatives Based on the Trimethyl Lock. ACS Med Chem Lett. 2015; 6(6):707-10. PMC: 4468398. DOI: 10.1021/acsmedchemlett.5b00146. View

19.

Dalhoff A . Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?. Eur J Clin Microbiol Infect Dis. 2014; 34(4):661-8. PMC: 7087824. DOI: 10.1007/s10096-014-2296-3. View

20.

Andriole V . The quinolones: past, present, and future. Clin Infect Dis. 2005; 41 Suppl 2:S113-9. DOI: 10.1086/428051. View